![The sights of Avalon Air Show 2025: Day Three [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/f-35-avalon-final-day-scaled-e1743079275404.jpg?#)
Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
Merck & Co.’s subcutaneous formulation of Keytruda has matched up to the original intravenous version on two blood concentration measurements, paving way for a potential FDA approval that could give patients a more convenient option of the widely used cancer drug.
Merck & Co.’s subcutaneous formulation of Keytruda has matched up to the original intravenous version on two blood concentration measurements, paving way for a potential FDA approval that could give patients a more convenient option of the widely used cancer drug.
